Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.
Prachi BhaveTasnia AhmedSerigne N LôAlexander N ShoushtariAnne ZarembaJudith M VersluisJoanna ManganaMichael WeichenthalLu SiThierry LesimpleCaroline RobertClaudia TrojanelloAlexandre WickyRichard HeywoodLena TranKathleen BattyFlorentia DimitriouAnna StansfeldClara AllayousJulia Katharina SchwarzeMeghan J MooradianOliver KleinInderjit MehmiRachel Roberts-ThomsonAndrea MaurichiHui-Ling YeohAdnan KhattakLisa ZimmerChristian U BlankEgle RamelyteKatharina C KählerSeverine RoyPaolo Antonio AsciertoOlivier MichielinPaul C LoriganDouglas B JohnsonRuth PlummerCeleste LebbeBart NeynsRyan J SullivanOmid HamidMario SantinamiGrant A McArthurAndrew M HaydonGeorgina V LongAlexander M MenziesMatteo S CarlinoPublished in: Journal for immunotherapy of cancer (2022)
While the ORR to anti-PD-1/ipilimumab was significantly higher than anti-PD-1 and PFS numerically higher, in this retrospective cohort this benefit did not translate to improved OS. Future trials should specifically include patients with acral melanoma, to help determine the optimal management of this important melanoma subtype.